Sirnaomics FY2025 loss narrowed 70.93% to US$15 million; revenue was no revenue

Reuters03-27

Sirnaomics FY2025 loss narrowed 70.93% to US$15 million; revenue was no revenue

Sirnaomics published an annual results announcement and reported no revenue, while loss for the year narrowed 70.93% to USD 14.6 million.
Administrative expenses fell 71% to USD 5 million and research and development expenses declined 50% to USD 10.3 million, which the company attributed to restructuring strategy and cost-saving measures.
Net cash used in operating activities decreased 53% to USD 9.2 million, and cash and cash equivalents rose to USD 13.5 million.
Bank borrowings were USD 2.3 million and current liabilities totaled USD 38.2 million.
Business updates included completion of preparatory work for FDA discussions on an adaptively designed Phase II/III pivotal trial for STP705 in non-melanoma skin cancer and submission of the full Phase I clinical study report for STP707 to the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072189), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622484146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622484146","market":"fut","top_or_hot":-1,"title":"Sirnaomics FY2025 loss narrowed 70.93% to US$15 million; revenue was no revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sirnaomics FY2025 loss narrowed 70.93% to US$15 million; revenue was no revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sirnaomics published an annual results announcement and reported no revenue, while loss for the year narrowed 70.93% to USD 14.6 million.\n        </li>\n<li>\n          Administrative expenses fell 71% to USD 5 million and research and development expenses declined 50% to USD 10.3 million, which the company attributed to restructuring strategy and cost-saving measures.\n        </li>\n<li>\n          Net cash used in operating activities decreased 53% to USD 9.2 million, and cash and cash equivalents rose to USD 13.5 million.\n        </li>\n<li>\n          Bank borrowings were USD 2.3 million and current liabilities totaled USD 38.2 million.\n        </li>\n<li>\n          Business updates included completion of preparatory work for FDA discussions on an adaptively designed Phase II/III pivotal trial for STP705 in non-melanoma skin cancer and submission of the full Phase I clinical study report for STP707 to the FDA.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SRNMF\">Sirnaomics Ltd.</a> published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072189), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sirnaomics FY2025 loss narrowed 70.93% to US$15 million; revenue was no revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSirnaomics FY2025 loss narrowed 70.93% to US$15 million; revenue was no revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sirnaomics FY2025 loss narrowed 70.93% to US$15 million; revenue was no revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Sirnaomics published an annual results announcement and reported no revenue, while loss for the year narrowed 70.93% to USD 14.6 million.\n        </li>\n<li>\n          Administrative expenses fell 71% to USD 5 million and research and development expenses declined 50% to USD 10.3 million, which the company attributed to restructuring strategy and cost-saving measures.\n        </li>\n<li>\n          Net cash used in operating activities decreased 53% to USD 9.2 million, and cash and cash equivalents rose to USD 13.5 million.\n        </li>\n<li>\n          Bank borrowings were USD 2.3 million and current liabilities totaled USD 38.2 million.\n        </li>\n<li>\n          Business updates included completion of preparatory work for FDA discussions on an adaptively designed Phase II/III pivotal trial for STP705 in non-melanoma skin cancer and submission of the full Phase I clinical study report for STP707 to the FDA.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SRNMF\">Sirnaomics Ltd.</a> published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072189), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL3qJm5N:1","article_id":"2622484146","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622484146","pubTimestamp":1774602148,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sirnaomics published an annual results announcement and reported no revenue, while loss for the year narrowed 70.93% to USD 14.6 million.Administrative expenses fell 71% to USD 5 million and research and development expenses declined 50% to USD 10.3 million, which the company attributed to restructuring strategy and cost-saving measures.Net cash used in operating activities decreased 53% to USD 9.2 million, and cash and cash equivalents rose to USD 13.5 million.Bank borrowings were USD 2.3 million and current liabilities totaled USD 38.2 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02257":"圣诺医药-B"},"translate_title":"圣诺制药2025财年亏损收窄70.93%至1500万美元；收入为无收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02257":0.9},"content_text":"Sirnaomics FY2025 loss narrowed 70.93% to US$15 million; revenue was no revenue\n    \n\n\n          Sirnaomics published an annual results announcement and reported no revenue, while loss for the year narrowed 70.93% to USD 14.6 million.\n        \n\n          Administrative expenses fell 71% to USD 5 million and research and development expenses declined 50% to USD 10.3 million, which the company attributed to restructuring strategy and cost-saving measures.\n        \n\n          Net cash used in operating activities decreased 53% to USD 9.2 million, and cash and cash equivalents rose to USD 13.5 million.\n        \n\n          Bank borrowings were USD 2.3 million and current liabilities totaled USD 38.2 million.\n        \n\n          Business updates included completion of preparatory work for FDA discussions on an adaptively designed Phase II/III pivotal trial for STP705 in non-melanoma skin cancer and submission of the full Phase I clinical study report for STP707 to the FDA.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072189), on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622484146","isCrawlerRequest":true}